Please ensure Javascript is enabled for purposes of website accessibility

Why Longeveron Stock Is Skyrocketing Today

By Keith Speights – Nov 24, 2021 at 12:25PM

Key Points

  • Longeveron stock is up by a multiple of 11 after the FDA gave a Rare Pediatric Disease designation for a heart medication last week.
  • The huge gain appears to be the result of short-sellers covering their positions.
  • This short squeeze could end soon.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

A short squeeze appears to be underway.

What happened

Shares of Longeveron (LGVN -1.20%) were skyrocketing 72.9% as of 11:51 a.m. ET on Wednesday after more than doubling earlier in the day. The company didn't report any new developments. So what's behind the huge gain?

An epic short squeeze appears to be underway. Longeveron announced on Nov. 18 that the U.S. Food and Drug Administration (FDA) granted a Rare Pediatric Disease designation to experimental drug Lomecel-B in treating a rare congenital heart defect. Since then, the company's shares have vaulted close to 11 times higher. The big increase was fueled by short-sellers closing their positions.

A $1 bill in a vise being squeezed.

Image source: Getty Images.

So what

Riding a short squeeze can result in significant returns very quickly, if you jump aboard early enough. The problem is that these squeezes typically don't last long. When a short squeeze ends, stocks usually fall nearly as rapidly as they rose.

Anyone considering buying shares of Longeveron at this point should exercise caution. The stock could soon give up much of its gains from the past few days. 

It's certainly good news that the FDA granted Rare Pediatric Disease designation to Lomecel-B. This puts Longeveron in a position to potentially receive a priority review voucher. Using a priority review voucher cuts the FDA's review time for an approval filing from 10 months to six months. However, Lomecel-B is still only in phase 2 testing. 

Now what

There are several milestones to look forward to with Longeveron after the short squeeze plays out. The company expects to kick off its phase 2 study evaluating Lomecel-B in Alzheimer's disease and a Japanese aging frailty study by the first quarter of 2022. The company also plans to report results from a phase 1/2 aging frailty study in the first quarter.

Keith Speights has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.